发明名称 |
STABLE HIGH STRENGTH PHARMACEUTICAL COMPOSITION OF LEVOLEUCOVORIN |
摘要 |
The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed. |
申请公布号 |
US2016081926(A1) |
申请公布日期 |
2016.03.24 |
申请号 |
US201414787984 |
申请日期 |
2014.04.30 |
申请人 |
APROFOL AG |
发明人 |
ULMANN Martin |
分类号 |
A61K9/08;A61K47/24;A61K47/20;A61K47/12;A61K31/519;A61K47/18 |
主分类号 |
A61K9/08 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical aqueous composition containing levoleucovorin, wherein the composition comprises the calcium salt, magnesium salt or zinc salt of levoleucovorin, optionally a pharmaceutically acceptable buffer compound, optionally a pharmaceutically acceptable antioxidant compound and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt. |
地址 |
Appenzell Steinegg CH |